Shanghai Pharmaceuticals (601607.SH): Cefuroxime Sodium for Injection and Aztreonam for Injection Pass Generic Drug Consistency Evaluation

Stock News11-10

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd. ("Shangyao Xinya"), recently received the "Drug Supplement Approval Notice" (Notice No.: 2025B05069, 2025B05110, 2025B05111) from the National Medical Products Administration (NMPA) for Cefuroxime Sodium for Injection and Aztreonam for Injection, indicating that these drugs have passed the consistency evaluation for generic drugs in terms of quality and efficacy.

Cefuroxime Sodium for Injection is indicated for the treatment of infections caused by susceptible microorganisms, including respiratory tract infections, ENT infections, urinary tract infections, skin and soft tissue infections, septicemia, meningitis, gonorrhea, bone and joint infections, as well as postpartum and gynecological infections. Aztreonam for Injection is used to treat infections caused by susceptible Gram-negative bacteria, including urinary tract infections (complicated and uncomplicated), lower respiratory tract infections, septicemia, skin and skin structure infections, intra-abdominal infections, and gynecological infections.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133091160?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 15:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133091160","market":"sh","top_or_hot":-1,"title":"Shanghai Pharmaceuticals (601607.SH): Cefuroxime Sodium for Injection and Aztreonam for Injection Pass Generic Drug Consistency Evaluation","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd. (\"Shangyao Xinya\"), recently received the \"Drug Supplement Approval Notice\" (Notice No.: 2025B05069, 2025B05110, 2025B05111) from the National Medical Products Administration (NMPA) for Cefuroxime Sodium for Injection and Aztreonam for Injection, indicating that these drugs have passed the consistency evaluation for generic drugs in terms of quality and efficacy.</p>\n<p>Cefuroxime Sodium for Injection is indicated for the treatment of infections caused by susceptible microorganisms, including respiratory tract infections, ENT infections, urinary tract infections, skin and soft tissue infections, septicemia, meningitis, gonorrhea, bone and joint infections, as well as postpartum and gynecological infections. Aztreonam for Injection is used to treat infections caused by susceptible Gram-negative bacteria, including urinary tract infections (complicated and uncomplicated), lower respiratory tract infections, septicemia, skin and skin structure infections, intra-abdominal infections, and gynecological infections.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals (601607.SH): Cefuroxime Sodium for Injection and Aztreonam for Injection Pass Generic Drug Consistency Evaluation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals (601607.SH): Cefuroxime Sodium for Injection and Aztreonam for Injection Pass Generic Drug Consistency Evaluation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-10 15:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd. (\"Shangyao Xinya\"), recently received the \"Drug Supplement Approval Notice\" (Notice No.: 2025B05069, 2025B05110, 2025B05111) from the National Medical Products Administration (NMPA) for Cefuroxime Sodium for Injection and Aztreonam for Injection, indicating that these drugs have passed the consistency evaluation for generic drugs in terms of quality and efficacy.</p>\n<p>Cefuroxime Sodium for Injection is indicated for the treatment of infections caused by susceptible microorganisms, including respiratory tract infections, ENT infections, urinary tract infections, skin and soft tissue infections, septicemia, meningitis, gonorrhea, bone and joint infections, as well as postpartum and gynecological infections. Aztreonam for Injection is used to treat infections caused by susceptible Gram-negative bacteria, including urinary tract infections (complicated and uncomplicated), lower respiratory tract infections, septicemia, skin and skin structure infections, intra-abdominal infections, and gynecological infections.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1133091160","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133091160","pubTimestamp":1762760540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd. (\"Shangyao Xinya\"), recently received the \"Drug Supplement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头","02607":"上海医药","BK0184":"上海国资改革","BK0099":"上海本地重组","BK0028":"国家队","BK0097":"医药电商","BK0020":"浦东新区","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK0209":"零售","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"上海医药（601607.SH）：注射用头孢呋辛钠、注射用氨曲南通过仿制药一致性评价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Xinya Pharmaceutical Co., Ltd. (\"Shangyao Xinya\"), recently received the \"Drug Supplement Approval Notice\" (Notice No.: 2025B05069, 2025B05110, 2025B05111) from the National Medical Products Administration (NMPA) for Cefuroxime Sodium for Injection and Aztreonam for Injection, indicating that these drugs have passed the consistency evaluation for generic drugs in terms of quality and efficacy.\nCefuroxime Sodium for Injection is indicated for the treatment of infections caused by susceptible microorganisms, including respiratory tract infections, ENT infections, urinary tract infections, skin and soft tissue infections, septicemia, meningitis, gonorrhea, bone and joint infections, as well as postpartum and gynecological infections. Aztreonam for Injection is used to treat infections caused by susceptible Gram-negative bacteria, including urinary tract infections (complicated and uncomplicated), lower respiratory tract infections, septicemia, skin and skin structure infections, intra-abdominal infections, and gynecological infections.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133091160","isCrawlerRequest":true}